PDE4 has been shown to be an effective therapeutic target for distinct inflammatory conditions, including asthma, chronic obstructive pulmonary disease (COPD), psoriasis, atopic dermatitis (AD), inflammatory bowel disease (IBD), rheumatic arthritis (RA), and neuroinflammation [5,6,7]. This evidence concerns the gene PDE4A and inflammatory bowel disease.